IOncology

Editor’s Note: The 13th Federation of Asian Clinical Oncology (FACO) Annual Meeting was grandly held in Shanghai on October 24–25, 2025. As a collaborative organization jointly initiated by the…

At the recent FACO 2025 Conference held in Shanghai, Dr. Joon Oh Park, President of KSMO and President-elect of FACO, shared his perspectives on the evolving landscape of cancer treatment…

Editor’s Note: The 2025 European Society for Medical Oncology (ESMO) Annual Congress was grandly held in Berlin, marking another milestone in global oncology research. In the field of hematologic malignancies,…

Editor’s Note: The 2025 European Society for Medical Oncology (ESMO) Annual Congress was grandly held in Berlin, marking another wave of major scientific breakthroughs in oncology. In the field of…

Editor’s Note: Promoting collaboration through exchange, and seeking mutual success through cooperation — on October 24, 2025, the 13th Federation of Asian Clinical Oncology (FACO) Annual Conference was grandly held…

The 13th International Conference of the Federation of Asian Clinical Oncology (FACO 2025) will be grandly held in Shanghai from October 24 to 25, 2025. The conference is jointly organized by the Federation of Asian Clinical Oncology (FACO), the Chinese Society of Clinical Oncology (CSCO), the Beijing CSCO Clinical Oncology Research Foundation, and the Eastern Clinical Oncology Research Center (ECCO). The theme is "Asian Clinical Oncology – Cooperation and Innovation," aiming to promote collaboration in drug research and new drug development, combine surgical and/or radiotherapy methods to jointly explore more efficient treatment options, and enhance the overall standards and effectiveness of cancer treatment.

Editor's Note: Immunotherapy has rapidly developed in recent years, achieving remarkable clinical results in the treatment of advanced bladder cancer. With the continued advancement of clinical research, the application of…

Editor’s Note: Patients carrying BRCA gene mutations face a significantly increased risk of developing breast cancer, and conventional therapies often yield suboptimal results. PARP inhibitors, by leveraging the mechanism of…

Editor’s Note: In recent years, immunotherapy, particularly PD-1/PD-L1 inhibitors, has profoundly transformed the treatment paradigm for triple-negative breast cancer (TNBC). The KEYNOTE-522 trial demonstrated that neoadjuvant immunotherapy combined with chemotherapy…

The 11th Qingdao Breast Disease Conference and the 9th “Langya Forum” were recently held in the beautiful coastal city of Qingdao. The event brought together leading experts and emerging talents in breast oncology from across China and beyond to share cutting-edge research, discuss innovative diagnostic and therapeutic strategies, and chart the future of breast disease management.